PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.03%
Negative EBIT growth while Biotechnology median is 0.00%. Seth Klarman would check if external or internal factors caused the decline.
-35.03%
Negative operating income growth while Biotechnology median is 0.00%. Seth Klarman would check if structural or cyclical issues are at play.
-37.55%
Negative net income growth while Biotechnology median is 0.00%. Seth Klarman would investigate factors dragging net income down.
-34.88%
Negative EPS growth while Biotechnology median is 0.00%. Seth Klarman would explore whether share dilution or profit declines are to blame.
-34.88%
Negative diluted EPS growth while Biotechnology median is 0.00%. Seth Klarman would look for the cause: weakened profitability or heavier share issuance.
2.03%
Share growth above Biotechnology median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
2.03%
Diluted share growth above 2x Biotechnology median. Jim Chanos would suspect undue issuance or heavy employee stock compensation.
No Data
No Data available this quarter, please select a different quarter.
9.51%
OCF growth of 9.51% while Biotechnology is zero. Walter Schloss might see a modest positive difference, which can compound over time.
9.65%
FCF growth of 9.65% while Biotechnology median is zero. Walter Schloss might see a slight edge that could compound over time.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
63.42%
OCF/share CAGR of 63.42% while Biotechnology median is zero. Walter Schloss might see a modest edge that can add up if momentum improves.
54.54%
OCF/share CAGR of 54.54% while Biotechnology median is zero. Walter Schloss might see a slight advantage that can compound if momentum builds.
-31.27%
Negative 3Y OCF/share CAGR while Biotechnology median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
85.15%
Net income/share CAGR of 85.15% while Biotechnology median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
56.20%
Net income/share CAGR of 56.20% while Biotechnology median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
-42.46%
Negative 3Y CAGR while Biotechnology median is 0.00%. Seth Klarman might see a pressing concern if the rest of the sector is stable or growing.
-24.53%
Negative 10Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman would see a firm-specific weakness if peers still expand equity.
-57.00%
Negative 5Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman suspects firm-specific weaknesses if peers grow equity mid-term.
-54.63%
Negative 3Y equity/share growth while Biotechnology median is 0.00%. Seth Klarman sees a short-term weakness if peers still expand net worth.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-2.92%
Assets shrink while Biotechnology median grows. Seth Klarman might see a strategic refocus or potential missed expansion if demand is present.
-9.07%
Negative BV/share change while Biotechnology median is -5.86%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-5.00%
Debt is shrinking while Biotechnology median is rising. Seth Klarman might see an advantage if growth remains possible.
41.18%
R&D growth of 41.18% while Biotechnology median is zero. Walter Schloss wonders if a slight increase yields a meaningful competitive edge.
22.12%
SG&A growth of 22.12% while Biotechnology median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.